PharmEasy Turnaround Analysis 2026: Docon Sells Thyrocare Stake
· 7 min read · Written by the BuyUnlistedShares desk. Information only, not investment advice.
API Holdings' subsidiary Docon Technologies raised ₹667.69 crore by selling a 10% stake in Thyrocare to meet debt obligations. With FY26 EBITDA turning positive, we review the group's balance sheet metrics and secondary market price trends.
Direct answer: Docon Technologies, a wholly owned subsidiary of API Holdings, offloaded a 10% stake in Thyrocare Technologies for ₹667.69 crore on 24 Oct 2025 to pare debt and bolster balance sheet liquidity. Tracked by BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002, API Holdings reported its first positive operational EBITDA in FY26.
Thyrocare Stake Monetisation and Liquidity Management
On 24 Oct 2025, Docon Technologies, a 100% subsidiary of API Holdings Limited, executed an open-market equity transaction selling a 10% stake in listed diagnostic chain Thyrocare Technologies. The transaction generated gross proceeds of ₹667.69 crore at an average price of ₹1,252 per share. Following the sale, Docon's promoter shareholding in Thyrocare reduced to 61%, while Thyrocare's total public market capitalisation stood at approximately ₹6,700 crore.
The proceeds were allocated toward debt reduction and working capital requirements for API Holdings, which acquired controlling interest in Thyrocare back in 2021. This equity sale followed a broader balance sheet realignment in September 2025, when API Holdings raised ₹1,700 crore through redeemable non-convertible debentures (NCDs) led by 360 One, pledging roughly 61% (3.23 crore shares) of Thyrocare as collateral to refinance existing liabilities. For additional context on this transaction, read our detailed analysis on how PharmEasy Just Sold Another Slice of Thyrocare. It May Be the Last One.
Financial Performance: Multi-Year Revenue and Margin Rebound
API Holdings' multi-year financial statements show a operational transition from deep losses toward margin recovery between FY23 and FY26. Consolidated revenue, which reached ₹6,644 crore in FY23 before contracting to ₹5,664 crore in FY24 as the group prioritized unit economics, recovered to ₹5,872 crore in FY25 and rose to ₹6,618.5 crore in FY26 (with reported figures reflecting around ₹6,869 crore, up 14% year-on-year).
Operational profitability shifted into positive territory during FY26, with consolidated EBITDA turning positive at ₹38 crore (and reported operating EBITDA reaching approximately ₹62.5 crore), reversing an EBITDA loss of ₹661 crore in FY25 and ₹1,421 crore in FY23. Net losses narrowed significantly from ₹5,211 crore in FY23 and ₹2,533 crore in FY24 to ₹1,572 crore in FY25 and ₹520 crore in FY26. Consequently, loss per share improved from -₹8.48 in FY23 to -₹0.74 in FY26, though legacy finance costs kept profit before tax in negative territory at -₹456 crore.
The financial trend chart illustrates revenue recovering to ₹6,618.5 crore in FY26 from ₹5,664 crore in FY24, alongside the group's first positive operating EBITDA of ₹38 crore in FY26.
Key Operational and Balance Sheet Metrics
API Holdings operates an integrated digital healthcare network combining consumer marketplace order delivery via PharmEasy, B2B technology-enabled distribution to local chemists via Retailio 1P, institutional hospital supply through Aknamed, and diagnostic lab services via Thyrocare and PharmEasy Labs. In August 2025, the group underwent a leadership realignment when co-founder Siddharth Shah stepped down as Chief Executive Officer and Rahul Guha, previously MD and CEO of Thyrocare, assumed the CEO role to steer operations.
The operational restructuring comes amid competitive pressures across the e-pharmacy and healthcare tech landscape, where API Holdings competes against players like Tata 1mg, Netmeds, and Reliance's Digital Health. Below is a summary of the core consolidated financial parameters recorded over recent financial years per audited disclosures and secondary market tracking as of 10 Oct 2026.
Unlisted Share Price Trends and Valuation Context
In private secondary market trading, PharmEasy's parent entity has seen valuation adjustments from its peak venture capital funding boom in 2021, when it commanded a peak valuation of $5.6 billion. Recent unlisted transaction indicators place the company's valuation range at $2.5–3.0 billion, driven by debt restructuring, rights issues, and secondary supply dynamics.
At BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002, we monitor private equity price trends alongside corporate filings to evaluate liquidity and capital structure updates. Between July 2026 and October 2026, indicative unlisted secondary prices moved from a low of ₹5.60 on 15 Jul 2026 to a high of ₹9.95 on 15 Sep 2026, before settling at ₹6.95 as of 10 Oct 2026. Investors can monitor live secondary pricing on the PharmEasy on BuyUnlistedShares profile page or run peer metrics on our broader Unlisted shares screener. For historical movements, see our note on why PharmEasy Unlisted Share Price Drops 11.7% in September 2026.
The unlisted share price chart demonstrates a move from a low of ₹5.60 on 15 Jul 2026 to a peak of ₹9.95 on 15 Sep 2026, before consolidating at ₹6.95 as of 10 Oct 2026.
Strategic Outlook and IPO Intentions
API Holdings previously filed draft initial public offering (DRHP) papers with SEBI but subsequently withdrew them to focus on internal restructuring, debt reduction via rights issues, and asset monetisation. The ₹667.69 crore raised from the Thyrocare stake sale, combined with positive EBITDA generation in FY26, marks an operational shift aimed at stabilizing net worth and managing interest coverage.
Market participants tracking potential public listing timelines can keep informed on mainboard and SME draft filings through our IPO calendar. Whether API Holdings initiates fresh public offer documentation in future quarters depends on sustaining net operational profitability and further managing outstanding borrowing levels.
To discuss unlisted share transactions, verify live secondary quotes, or review audited annual reports, reach out directly to BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002 by visiting our enquiry desk.
| Item | Value | As of |
|---|---|---|
| Indicative price | ₹6.95 | 13 Oct 2026 |
| Lot size | 3335 shares | 13 Oct 2026 |
| Minimum investment | ₹25,012 | 13 Oct 2026 |
| Market cap | ₹9,538 Cr | 13 Oct 2026 |
| Face value | ₹1 | 13 Oct 2026 |
| Book value | ₹1.75 | 13 Oct 2026 |
| ISIN | INE0DJ201029 | 13 Oct 2026 |
| Sector | Healthcare | 13 Oct 2026 |
| Listing status | UNLISTED | 13 Oct 2026 |
Frequently Asked Questions
What was the primary purpose of Docon selling its Thyrocare stake?
Docon Technologies offloaded a 10% stake in Thyrocare for ₹667.69 crore on 24 Oct 2025 to generate liquidity for parent firm API Holdings, earmarking proceeds for debt reduction and operational working capital needs.
Did PharmEasy's parent company achieve profitability in FY26?
API Holdings recorded its first full-year positive operating EBITDA of ₹38 crore (with reported operational EBITDA around ₹62.5 crore) in FY26, reversing an EBITDA loss of ₹661 crore in FY25, though legacy interest costs kept net PAT at -₹520 crore.
Are PharmEasy unlisted shares suitable for retail investors?
We do not make that call. Unlisted secondary shares carry specific risks including reduced trading liquidity, valuation volatility, and extended holding timelines compared to exchange-listed equities. Investors should consult a qualified financial advisor to evaluate their risk tolerance.
What is the current unlisted share price of PharmEasy?
As of 10 Oct 2026, the indicative unlisted share price for API Holdings (PharmEasy) is ₹6.95 per share, down from a peak of ₹9.95 recorded on 15 Sep 2026. Indicative prices reflect negotiated secondary transactions and are subject to market conditions.
Is PharmEasy currently listed on the NSE or BSE?
No, PharmEasy's parent entity API Holdings Limited is not listed on public stock exchanges. Although draft IPO papers were filed previously, they were withdrawn, and equity shares currently trade through private unlisted share desks.
Information only, not investment advice. Unlisted and pre-IPO securities carry liquidity, valuation and listing-timing risk; read the offer document and consult a SEBI-registered investment adviser for advice specific to your situation.
